Digital Science, a division of Macmillan Publishers Ltd., today announced an investment in Toronto-based startup 1DegreeBio. The company was founded by alumni from the Structural Genomics Consortium to help their fellow scientists more efficiently discover and select biological reagents — essential ingredients in almost all biomedical research. The 1DegreeBio platform (http://www.1degreebio.org/) provides not only a growing online database of research products, but also reviews and validation data posted by researchers, allowing scientists to make more informed decisions. 1DegreeBio is currently focusing on the $2bn antibody market, but will be extending their service to cover other reagents and products.
“We are very excited to have teamed up with Digital Science,” said Alex Hodgson, co-founder and Managing Director of 1DegreeBio. “This partnership will allow us to expand our platform to make it even easier for scientific community to connect with top quality antibodies and in the near future, all essential research products and reagents. ”
1DegreeBio joins Digital Science’s other portfolio companies, including SureChem, BioData and Symplectic. Together these provide a range of state-of-the-art software and services that make research more effective. For more information on Digital Science, its portfolio companies and products, visit http://www.digital-science.com/products
“1DegreeBio has all the characteristics we look for in a promising new business: a deep understanding of science, technological excellence in everything they do and strong entrepreneurial flair,” said Timo Hannay, Managing Director of DIgital Science. “We’re delighted to welcome them to our growing network of partners and products, where they fill a very important need for the researchers we serve.”
“Antibodies are among the most commonly used reagents in biomedicine, yet are subjected to the least effective quality control,” says Dr. Aled Edwards, Director and CEO of the Structural Genomics Consortium. “1DegreeBio has developed a sustainable business model for data sharing to tackle this problem – their platform rewards companies that sell great products and provides scientists rapid and open access to the best information. This is great news for biomedical research.”